Karyopharm Therapeutics has priced its stock at $16 a share - the top of its proposed range as of Friday - and plans to become the ninth Bay State biotech to go public so far this year when it starts trading Wednesday on the Nasdaq under the symbol, “KPTI.” At that price, the Natick-based oncology biotech will sell 6.8 million shares to raise $104 million, minus fees. That’s the second highest amount of any biotech that’s gone public locally in Massachusetts so far this year, and the actual amount will probably be even higher, assuming another 1 million shares the company set aside to cover overallotments are sold as well.
Help employers find you! Check out all the jobs and post your resume.
